Lipocine (LPCN) said Tuesday that it signed an exclusive supply and distribution agreement with Pharmalink to commercialize its Tlando oral testosterone replacement therapy in the Gulf Cooperation Council or GCC countries.
The company said it received an upfront payment from Pharmalink but did not disclose the amount. The company said it will supply Tlando to Pharmalink at an agreed price once it secures marketing authorizations in the GCC countries of the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman.
As part of the deal, Pharmalink will have exclusive rights to Tlando in the GCC countries, covering the product's promotion, distribution, and sale.
Price: 5.06, Change: +0.07, Percent Change: +1.40
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.